-
Product Insights
NewNet Present Value Model: I-Mab’s Uliledlimab
Empower your strategies with our Net Present Value Model: I-Mab's Uliledlimab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TRV-045 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TRV-045 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TRV-045 in Epilepsy Drug Details: TRV-045 is under development for the treatment of...
-
Product Insights
Opium Withdrawal Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Opium Withdrawal Syndrome - Drugs In Development, 2023’, provides an overview of the Opium Withdrawal Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium Withdrawal Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Chemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Opium (Opioid) Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Opium (Opioid) Addiction - Drugs In Development, 2023’, provides an overview of the Opium (Opioid) Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PB-1002 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PB-1002 in Solid Tumor Drug Details: PB-1002 is under development for the treatment of hormone...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MK-1092 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-1092 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-1092 in Type 1 Diabetes (Juvenile Diabetes) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa in Epidermolysis Bullosa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa in Epidermolysis Bullosa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Activate Lamb-3...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TQB-2858 in Hematological Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TQB-2858 in Hematological Tumor Drug Details: TQB-2858 is under development for the treatment of advanced...